Pre-leukemic evolution of hematopoietic stem cells: The importance of early mutations in leukemogenesis

Leukemia

Volumn 28, Issue 12, 2014, Pages 2276-2282

  Corces Zimmerman, M R ^a   Majeti, R ^a,b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; PROTEIN; TEN ELEVEN TRANSLOCATION 2; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL RENEWAL; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLONAL EVOLUTION; COLONY FORMING UNIT GM; COLONY FORMING UNIT S; DNA SEQUENCE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SEQUENCING; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MINIMAL RESIDUAL DISEASE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRE LEUKEMIC HEMATOPOIETIC STEM CELL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; WILD TYPE; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; GENOMICS; LEUKEMIA; METABOLISM; MORTALITY; MOUSE; MUTATION; NEOPLASM, RESIDUAL; PATHOLOGY; PRECANCER;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENOMICS; HEMATOPOIETIC STEM CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA; MICE; MUTATION; NEOPLASM, RESIDUAL; PRECANCEROUS CONDITIONS;

EID: 84926991134     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.211     Document Type: Review

References (55)

1. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
2. Jones S, Chen W-D, Parmigiani G, Diehl F, Beerenwinkel N, Antal T et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008; 105: 4283-4288.
3. Araten DJ, Golde DW, Zhang RH, Thaler HT, Gargiulo L, Notaro R et al. A quantitative measurement of the human somatic mutation rate. Cancer Res 2005; 65: 8111-8117.
4. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
5. Fialkow PJ, Singer JW, Raskind WH, W AJ, Jacobson RJ, Bernstein ID et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987; 317: 468-473.
6. Fialkow PJ, Janssen JW, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. Blood 1991; 77: 1415-1417.
7. Ferraris AM, Raskind WH, Bjornson BH, Jacobson RJ, Singer JW, Fialkow PJ. Heterogeneity of B cell involvement in acute nonlymphocytic leukemia. Blood 1985; 66: 342-344.
8. Kwong YL, Wong KF, Chan V, Chan CH. Persistence of AMLI Rearrangement in Peripheral Blood Cells in t(8;21). Cancer Genet Cytogenet 1996; 54: 151-154.
9. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789-4796.
10. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521-7526.
11. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993; 363: 358-360.
12. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499-1503.
13. Zuna J, Burjanivova T, Mejstrikova E, Zemanova Z, Muzikova K, Meyer C et al. Covert preleukemia driven by MLL. Gene Fusion 2009; 107: 98-107.
14. Zuna J, Muzikova K, Ford AM, Maia AT, Krejci O, Tousovska K et al. Pre-natal, clonal origin of acute lymphoblastic leukaemia in triplets. Leuk Lymphoma 2003; 44: 2099-2102.
15. Van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 2011; 117: 6247-6254.
16. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998; 95: 4584-4588.
17. Gale KB, Ford aM, Repp R, Borkhardt a, Keller C, Eden OB et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997; 94: 13950-13954.
18. Maia AT, Tussiwand R, Cazzaniga G, Rebulla P, Colman S, Biondi A et al. Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes Cancer 2004; 40: 38-43.
19. Greaves M. Pre-natal Origins of Childhood Leukemia. Rev Clin Exp Hematol 2003; 3: 233-245.
20. Horsley SW, Colman S, Mckinley M, Bateman CM, Jenney M, Chaplin T et al. Genetic Lesions in a Preleukemic Aplasia Phase in a Child with Acute Lymphoblastic. Leukemia 2008; 340: 333-340.
21. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
22. Knuutila S, Teerenhovi L, Larramendy ML, Elonen E, Franssila KO, Nylund SJ et al. Cell lineage involvement of recurrent chromosomal abnormalities in hematologic neoplasms. Genes Chromosomes Cancer 1994; 10: 95-102.
23. Jonas D, Lübbert M, Kawasaki ES, Henke M, Bross KJ, Mertelsmann R et al. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 1992; 79: 1017-1023.
24. Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R et al. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 1997; 97: 99-106.
25. Nitta M, Kato Y, Strife A, Wachter M, Fried J, Perez A et al. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 1985; 66: 1053-1061.
26. Juneja HS, Weiner R. Presence of the Philadelphia chromosome (Ph 1) in pokeweed mitogen stimulated lymphocytes during chronic phase of chronic myelocytic leukemia (CML). Cancer Genet Cytogenet 1981; 4: 39-44.
27. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125-130.
28. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81: 2898-2902.
29. Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004; 351: 657-667.
30. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118: 5565-5572.
31. Chomel J-C, Bonnet M-L, Sorel N, Bertrand A, Meunier M-C, Fichelson S et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657-3660.
32. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
33. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
34. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
35. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20: 246-259.
36. Jamieson CHM, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006; 103: 6224-6229.
37. Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007; 12: 367-380.
38. Chu SH, Heiser D, Li L, Kaplan I, Collector M, Huso D et al. FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm. Cell Stem Cell 2012; 11: 346-358.
39. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell 2011; 20: 1-14.
40. Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
41. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44: 23-31.
42. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659.
43. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff S et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic. Leukemic 2008; 28: 1377-1380.
44. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
45. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.
46. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2010; 30: 1009-1019.
47. Majeti R, Chao MP, Alizadeh Aa, Pang WW, Jaiswal S, Gibbs KD et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-299.
48. Jan M, Chao MP, Cha AC, Alizadeh Aa, Gentles AJ, Weissman IL et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011; 108: 5009-5014.
49. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118.
50. Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548-2553.
51. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
52. Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MWM et al. Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia. Blood 2013; 122: 100-108.
53. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329-341.
54. Jamieson CH. Chronic myeloid leukemia stem cells. Hematol Am Soc Hematol Educ Program 2008; 1: 436-442.
55. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-2231.